NCT05513586 - A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Primary Immunodeficiency Diseases (PID)

Interventions

DRUG

TAK-771

Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

Trial Locations (9)

Nagoya University Hospital, Nagoya

Hospital of University of Occupational and Environmental Health, Kitakyushu

Kanagawa Children's Medical Center, Yokohama

Tokyo Medical Dental University Hospital, Bunkyo-ku

Kyushu University Hospital, Fukuoka

Gifu University Hospital, Gifu

Hiroshima University Hospital, Hiroshima

Saitama Prefectual Children's Medical Center, Saitama

Shizuoka Childrens Hospital, Shizuoka